Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia

Nuclear Medicine and Biology

Volumn 39, Issue 6, 2012, Pages 871-882

  Laurens, Evelyn ^a   Yeoh, Shinn Dee ^b   Rigopoulos, Angela ^c   Cao, Diana ^c   Cartwright, Glenn A ^c   O'Keefe, Graeme J ^b   Tochon Danguy, Henri J ^b,d   White, Jonathan M ^a   Scott, Andrew M ^b,c,d   Ackermann, Uwe ^b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Hypoxia; LCMS; Radiolabelling; Radiotracer metabolism; SK RC 52 tumor model

Indexed keywords

4 NITROPHENYL SULFOXIDE; CHLORIDE; FLUOROETHYL AZIDE F 18; HALOETHYLSULFOXIDE; N (2 CHLOROETHYL) N [[1 [2 FLUOROETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL] 4 (4 NITROPHENYLSULFINYL)BENZENEAMINE F 18; N (2 FLUOROETHYL) 4 (4 NITROPHENYLSULFINYL) N (PROP 2 YNYL)ANILINE FLUOROETHYL F 18; NUCLEOPHILE; SULFOXIDE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BAGG ALBINO MOUSE; CHEMICAL REACTION; CLICK CHEMISTRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER; NEOPLASM; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; TUMOR HYPOXIA; TUMOR MODEL;

ANIMALS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RATS; SULFOXIDES;

EID: 84863992098     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.004     Document Type: Article

References (34)

1. Lara P.C., Lloret M., Clavo B., Apolinario R.M., Henriquez-Hernandez L.A., Bordón E., et al. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP overexpression. Radiat Oncol 2009, 4:29-33.
2. Sasabe E., Zhou X., Li D., Oku N., Yamamoto T., Osaki T. The involvement of hypoxia inducible factor-1 alpha in the susceptibility to gamma rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 2007, 120:268-277.
3. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996, 379:88-91.
4. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
5. Sun Z.Y., Botros E., Su A.D., Kim Y., Wang E., Baturay N.Z., et al. Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. J Med Chem 2000, 43:4160-4168.
6. Denny W.A. The role of hypoxia activated prodrugs in cancer therapy. Lancet Oncol 2000, 1:25-29.
7. Rajendran J.G., Hendrickson K.R.G., Spence A.M., Muzi M., Krohn K.A., Mankoff D.A. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006, 33:S44-S53.
8. Stone H.B., Brown J.M., Phlilips T.L., Sutherland R.M. Oxygen in human tumors: correlations between methods of measurements and response to therapy. Radiat Res 1993, 136:422-434.
9. 2 tension measurements. Cancer Res 1991, 51:3316-3322.
10. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50.
11. Markus R., Donnan G.A., Kazui S., Read S., Hirano T., Scott A.M., et al. Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following acute ischemic stroke. NeuroImage 2002, 16:425-433.
12. Brady F., Luthra K.S., Brown G.D., Osman S., Aboagye E., Saleem A., et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 2001, 7(18):1863-1892.
13. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995, 22:265-280.
14. Foo S.S., Abbott D.F., Lawrentschuk N., Scott A.M. Functional imaging of intratumoural hypoxia. J Mol Imag Biol 2004, 6(5):291-305.
15. 18F-fluoromisonidazole. Semin Nucl Med 2007, 37(6):451-461.
16. 18F]-2-fluoro-2'-deoxyglucose). Strahlenther Onkol 2004, 10:616-622.
17. 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 2000, 48:228-235.
18. 18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009, 36:209-218.
19. 18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010, 37:1663-1668.
20. 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010, 37:2048-2052.
21. Zha Z., Zhu L., Liu Y., Du F., Gan H., Qiao J., et al. Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging. Nucl Med Biol 2011, 38:501-508.
22. Falzon C.L., Ackermann U., Spratt N., Tochon-Danguy H.J., White J., Howells D., et al. F-18 Labelled N,N-bis-haloethylamino-phenylsulfoxides - a new class of compounds for the imaging of hypoxic tissue. J Label Compd Radiopharm 2006, 49:1089-1103.
23. Demko Z.P., Sharpless K.B. An intramolecular [2 + 3] cycloaddition route to fused 5-heterosubstituted tetrazoles. Org Lett 2001, 25:4091-4094.
24. 18F-labeled potential myocardial blood flow tracers. Nucl Med Biol 2001, 28:683-693.
25. Lemaire C., Plenevaux A., Aerts J., Del Fiore A., Brihaye C., Le Bars D., et al. Solid phase extraction - an alternative to the use of rotary evaporators for solvent removal in the rapid formulation of PET radiopharmaceuticals. J Label Compd Radiopharm 1999, 42:63-75.
26. Browne J., de Pierro A.B. A row-action alternative to the EM algorithm for maximizing likelihood in emission tomography. IEEE Trans Med Imaging 1996, 15(5):687-699.
27. 18F]2-fluoroethyl azide and 5-ethynyl-2'-deoxyuridine. J Label Compd Radiopharm 2011, 54:260-266.
28. 18F]fluoroethylazide for positron emission tomography. Bioconjugate Chem 2007, 18:989-993.
29. Yoshihara S., Makishima M., Suzuki N., Ohta S. Metabolic activation of bisphenol a by rat liver S9 fraction. Toxicological Sciences 2001, 62:221-227.
30. Ackley D.C., Rockich K.T., Baker T.R. Methods in Pharmacology and Toxicology: Optimization in Drug Discovery: In Vitro Methods 2004, 151-162. Humana Press, Springer. 1st ed.
31. Lee S.Y., Choe Y.S., Kim D.H., Park B.N., Kim S.E., Choi Y., et al. A simple and efficient in vitro method for metabolism studies of radiotracers. Nucl Med Biol 2001, 38:391-395.
32. 18F-FMISO) positron emission tomography. BJU Int 2005, 96:540-546.
33. 124I-cG250 PET/CT. Urol Oncol 2011, 29(4):411-420.
34. Hevey R.C., Babson J., Maycock A.L., Abeles R.H. Highly specific enzyme inhibitors. inhibition of plasma amine oxidase. JACS 1973, 95:6125-6127.